United States Idiopathic Hypersomnia Treatment Market: Jazz Pharmaceuticals & Emerging Competitors

Market Size and Forecast:

Global Idiopathic Hypersomnia Treatment Market is expected to reach growth at a Significant CAGR during the forecast period 2025-2032.

The Idiopathic Hypersomnia Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/idiopathic-hypersomnia-treatment-market?ca

Idiopathic Hypersomnia (IH) treatment focuses on managing excessive daytime sleepiness and improving wakefulness using medications such as modafinil, solriamfetol, and low-sodium oxybate. Behavioral therapies and lifestyle adjustments complement pharmacological approaches to enhance sleep quality and daily functioning. Ongoing research into the neurological mechanisms of IH is fostering the development of more targeted and effective therapies.

Recent Key Developments of United States and Japan:

USA

June 5, 2025: Avadel Pharmaceuticals received Orphan Drug Designation (ODD) from the FDA for Lumryz (extended-release sodium oxybate) for IH, providing regulatory and financial incentives for the development of its once-nightly dosing regimen for this rare disorder.

Ongoing Trend (Jul-Sept 2025): The market saw sustained interest in once-nightly sodium oxybate formulations (like Lumryz), driven by their potential to improve patient adherence and quality of life by eliminating the nocturnal arousal required for existing twice-nightly dosing (like Xywav).

Japan

September 12, 2025: Takeda's Phase 2 study of TAK-360 (an oral orexin receptor 2 agonist) for adults with IH was updated and verified on ClinicalTrials.gov, confirming active clinical investigation of a potential first-in-class, non-oxybate therapy for IH in Japan.

Ongoing Trend (Jul-Sept 2025): The Japanese market saw a strong focus on advancing narcolepsy treatments (like Takeda's oveporexton) based on the orexin mechanism, with positive Phase 3 results in narcolepsy potentially accelerating the development and regulatory pathway for related orexin agonists targeting IH in Japan.

List of the Key Players in the Idiopathic Hypersomnia Treatment Market:

Jazz Pharmaceuticals plc
Harmony Biosciences Holdings, Inc.
AVADEL PHARMACEUTICALS PLC
Zevra Therapeutics, Inc.
Teva Pharmaceuticals USA, Inc.
Mylan N.V.
Hoffmann-La Roche Limited
BIOPROJET
Theranexus
Shionogi Inc.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/idiopathic-hypersomnia-treatment-market?ca

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Idiopathic Hypersomnia Treatment Market:

➥ By Treatment Type: Non-Stimulant Wake-Promoting Medications, CNS Depressants, Psychostimulants, Others

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=idiopathic-hypersomnia-treatment-market?ca

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Idiopathic Hypersomnia Treatment Market market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Idiopathic Hypersomnia Treatment Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Idiopathic Hypersomnia Treatment Market leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Idiopathic Hypersomnia Treatment Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Idiopathic Hypersomnia Treatment Market in 2025?
◆ What is the projected growth rate of the Idiopathic Hypersomnia Treatment Market through 2033?
◆ Who are the key players in the Idiopathic Hypersomnia Treatment Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.